clinicians might expect such attributes to enhance the ability of these drugs to favorably modulate the risk of macrovascular and microvascular events [35, 36]
Positive clinical and structural brain outcomes from the APOLLOE4 Phase 3 program continue to strengthen the case for valiltramiprosate as a potential breakthrough oral treatment for the high-risk APOE4 population, said David Watson, PhD, founder & principal investigator, Alzheimers & Research Treatment Center in a statement
Unlike current GLP-1 agonists like semaglutide or dual GIP/GLP-1 therapies like tirzepatide, retatrutide adds glucagon receptor activation for enhanced metabolic benefits
Due to their mechanism of action, which is independent from cell function, SGLT2 inhibitors do not cause hypoglycemia
This may cause side effects to feel stronger initially but does not change the total dose or ultimate weight-loss benefit